We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
-5.71%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$810M
AUM Growth
-$260M
Cap. Flow
-$189M
Cap. Flow %
-23.28%
Top 10 Hldgs %
32%
Holding
105
New
11
Increased
30
Reduced
42
Closed
19

Top Buys

Rank Stock Value
1
SYK icon
Stryker
SYK
+$17.2M
2
VEEV icon
Veeva Systems
VEEV
+$16.8M
3
BSX icon
Boston Scientific
BSX
+$15.5M
4
ABT icon
Abbott
ABT
+$12.6M
5
WAY
Waystar Holding Corp
WAY
+$9.09M

Top Sells

Rank Stock Value
1
COO icon
Cooper Companies
COO
+$22M
2
VERA icon
Vera Therapeutics
VERA
+$21.3M
3
MDT icon
Medtronic
MDT
+$19.7M
4
DHR icon
Danaher
DHR
+$17.2M
5
ALGN icon
Align Technology
ALGN
+$16M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BSX icon
1
Boston Scientific
BSX
$74.2B
$39.2M 4.84%
625,000
+193,793
+45% +$15.5M
REGN icon
2
Regeneron Pharmaceuticals
REGN
$82.1B
$37.2M 4.59%
48,100
-13,300
-22% -$10.2M
LLY icon
3
Eli Lilly
LLY
$1.08T
$31M 3.83%
33,715
-8,505
-20% -$8.62M
INSM icon
4
Insmed
INSM
$29B
$26.1M 3.22%
159,760
+46,175
+41% +$7.1M
CVS icon
5
CVS Health
CVS
$120B
$24.2M 2.98%
336,500
+1,000
+0.3% +$77K
GILD icon
6
Gilead Sciences
GILD
$168B
$23.4M 2.88%
167,750
+41,600
+33% +$5.83M
TMO icon
7
Thermo Fisher Scientific
TMO
$224B
$20.3M 2.51%
41,340
+7,700
+23% +$4.18M
BIIB icon
8
Biogen
BIIB
$30.1B
$20M 2.47%
109,100
+16,750
+18% +$3.09M
VRTX icon
9
Vertex Pharmaceuticals
VRTX
$134B
$19.4M 2.4%
43,485
+9,230
+27% +$4.3M
ALHC icon
10
Alignment Healthcare
ALHC
$2.74B
$18.6M 2.29%
1,053,450
+44,000
+4% +$884K
ISRG icon
11
Intuitive Surgical
ISRG
$142B
$17M 2.1%
36,846
-11,154
-23% -$5.64M
COR icon
12
Cencora
COR
$63.7B
$16.5M 2.03%
52,375
-11,000
-17% -$3.84M
SYK icon
13
Stryker
SYK
$134B
$15.7M 1.94%
+47,800
New +$17.2M
ABBV icon
14
AbbVie
ABBV
$442B
$15.6M 1.92%
71,575
-39,000
-35% -$8.65M
VEEV icon
15
Veeva Systems
VEEV
$38.4B
$15M 1.85%
+85,300
New +$16.8M
MCK icon
16
McKesson
MCK
$105B
$14.6M 1.8%
16,850
-8,750
-34% -$7.81M
JAZZ icon
17
Jazz Pharmaceuticals
JAZZ
$16.1B
$14.3M 1.77%
75,890
+1,860
+3% +$325K
GH icon
18
Guardant Health
GH
$22.2B
$13.4M 1.65%
145,000
+65,000
+81% +$6.53M
NBIX icon
19
Neurocrine Biosciences
NBIX
$16.5B
$13.3M 1.64%
100,841
-24,650
-20% -$3.27M
EW icon
20
Edwards Lifesciences
EW
$54B
$13.1M 1.61%
163,000
-30,500
-16% -$2.51M
MDGL icon
21
Madrigal Pharmaceuticals
MDGL
$12.4B
$12.6M 1.55%
24,050
+4,500
+23% +$2.15M
UNH icon
22
UnitedHealth
UNH
$365B
$12.3M 1.52%
45,500
-9,400
-17% -$2.8M
PRCT icon
23
Procept Biorobotics
PRCT
$1.31B
$11.9M 1.47%
475,000
-136,000
-22% -$3.83M
BMRN icon
24
BioMarin Pharmaceuticals
BMRN
$13.5B
$11.7M 1.44%
207,000
-8,000
-4% -$466K
ABT icon
25
Abbott
ABT
$190B
$11.5M 1.42%
+112,000
New +$12.6M
1
2 3 4 5

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return
BC
Brio Consultants San Francisco, California $818M AUM 13.48% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2026 Portfolio in Review

As of Q1 2026, Rhenman & Partners Asset Management held 105 positions worth $810M, down 24% from $1.07B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $189M in Q1 2026, closing 19 positions and reducing 42 holdings. Its most notable exit was Vera Therapeutics, an estimated $21.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Rhenman & Partners Asset Management opened a new position in Stryker worth $15.7M.

  • Rhenman & Partners Asset Management's largest Q1 2026 buy was Stryker: 47,800 shares worth $15.7M.
  • Rhenman & Partners Asset Management added most to Boston Scientific in Q1 2026, an estimated $15.5M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2026 reduction was Cooper Companies, cutting an estimated $22M.
  • Rhenman & Partners Asset Management fully exited Vera Therapeutics in Q1 2026, selling an estimated $21.3M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 32% of its $810M portfolio in Q1 2026.
  • Rhenman & Partners Asset Management opened 11 new positions and closed 19 in Q1 2026.
  • Rhenman & Partners Asset Management's portfolio value fell 24% quarter-over-quarter to $810M.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2026, filed 14 May 2026.